Buy Rating Affirmed for Spruce Biosciences Amid Anticipated Positive Clinical Trial Outcomes and Strong Financial Position
Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Spruce Biosciences (SPRB Research Report). The associated price t...
TipRanks Financial Blog·1y ago